Long-term outcomes following first short-term clinically important deterioration in COPD

Respiratory Research

Table 2 Odds/Risk of long-term adverse outcomes based on CIDs in the first 6 months of the TORCH study (ITT population)

Outcome	CID+ population (N = 2870)	CID- population (N = 2422)	CID+ vs CID-, OR (95% CI)
≥100 mL decrease in FEV₁^a, n (%)	2004 (70)	1296 (54)	2.00 (1.78, 2.24)*
≥200 mL decrease in FEV₁^a, n (%)	1696 (59)	1018 (42)	1.97 (1.77, 2.20)*
≥4-unit increase in SGRQ^a, n (%)	1516 (67)	930 (53)	1.82 (1.60, 2.07)*
≥8-unit increase in SGRQ^a, n (%)	1342 (59)	827 (47)	1.65 (1.45, 1.88)*
Moderate-to-severe COPD exacerbation^b, n (%)	2082 (73)	1450 (60)	1.61^c (1.50, 1.72)*
Hospitalization events^b, n (%)	797 (28)	491 (20)	1.55^c (1.38, 1.73)*
Risk (HR) of all-cause mortality^b, n (%)	237 (8)	160 (7)	1.41^c (1.15, 1.72)*

*P < 0.001, ^arisk of deterioration at 36-months assessed from the pre-randomization period; ^brisk of a new exacerbation or all-cause death assessed from Week 24; ^cdata report HR (95% CI)
CID clinically important deterioration, CID+ presence of a CID within 6 months of enrollment into the study, CID- absence of a CID within 6 months of enrollment into the study, FEV₁ forced expiratory volume in 1 s, HR hazard ratio, ITT intent-to-treat, OR odds ratio, SGRQ St George’s Respiratory Questionnaire, TORCH TOwards a Revolution in COPD Health

ISSN: 1465-993X